Abstract 327P
Background
SARS-CoV-2 is a novel coronavirus of zoonotic origin that emerged in China and now is spreading worldwide. 71 838 cases have been registered in Kazakhstan. At the moment, 3 585 of which died. The risk of coronavirus infection in oncohematological patients is much higher, due to a reduced immune status and immunosuppressive therapy, which they receive, as well as comorbidity in majority of patients.
Methods
We included all consecutive adult patients with oncohematologic diseases admitted to KazIOR, the Hematology Department, with laboratory-confirmed COVID-19 infection between June 15 and July 15, 2020. A confirmed case of COVID-19 was defined by a positive result on a real-time RT-PCR assay and radiological evidence of pneumonia CT-scan.
Results
The median patient age was 49 (range, 18–81) years, 64% were male. The median duration of symptoms before the COVID-19 PCR assay was was 4 (range, 0–22) days. Multiple myeloma (MM) was eleven patients, Acute Lymphoblastic leukemia (ALL)-three patients, Non-Hodgkin lymphoma (NHL)-three patients, Hodgkin Lymphoma (HL)-five patients, Chronic Lymphocytic leukemia (CLL)-two patients. 16 from 25 patients (64%) received chemotherapy at the time of COVID-19 diagnosis, which was registered during the treatment or after that. 13 patients had clinical symptoms, such as fever (n = 56%), cough (n = 25.8%), and shortness of breath (n = 48%), twelve patients were asymptomatic. CT scan of the chest was performed in 14 patients and bilateral ground glass opacities were evident in all cases. Five patients died, among them three patients died from the acute respiratory distress syndrome (ARDS), two patients with ALL had a progression of the process during chemotherapy, which was aggravated by the ARDS syndrome and acute renal failure.
Conclusions
Despite positive COVID-19 status patients with oncohematologic diseases require urgent specific treatment. The virus SARS-CoV-2 worsens the condition of comorbid patients, the response to treatment, increases the possible emergence of resistant and refractory patients, due to the lengthening of the inter-course periods. Risk factors as older age, and comorbidities such as diabetes, hypertension, or cardiac disease can aggravate patient condition which were confirmed by scientific research data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session